rH/E distinguishes the HER2-enriched subtype breast cancer better than ERBB2 or ESR1 expression alone, which can help to more accurately identify the subgroups of tumor which are predominantly driven by HER2 or ER in the HR+/HER2+ population. This evidence concerns the gene HR and breast carcinoma.